[go: up one dir, main page]

MX2020001319A - Modulacion de la actividad del factor de crecimiento epidermico de union a la heparina para curar la membrana timpanica. - Google Patents

Modulacion de la actividad del factor de crecimiento epidermico de union a la heparina para curar la membrana timpanica.

Info

Publication number
MX2020001319A
MX2020001319A MX2020001319A MX2020001319A MX2020001319A MX 2020001319 A MX2020001319 A MX 2020001319A MX 2020001319 A MX2020001319 A MX 2020001319A MX 2020001319 A MX2020001319 A MX 2020001319A MX 2020001319 A MX2020001319 A MX 2020001319A
Authority
MX
Mexico
Prior art keywords
tympanic membrane
modulation
growth factor
sustained release
epidermal growth
Prior art date
Application number
MX2020001319A
Other languages
English (en)
Inventor
Luke Santa Maria Peter
Peter Yang Yunzhi
Kim Sungwoo
DOMVILLE - LEWIS Chloe
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2020001319A publication Critical patent/MX2020001319A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0076—Sprayable compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
    • A61F11/20—Ear surgery
    • A61F11/202—Surgical middle-ear ventilation or drainage, e.g. permanent; Implants therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/18—Internal ear or nose parts, e.g. ear-drums
    • A61F2002/183—Ear parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Acoustics & Sound (AREA)
  • Physics & Mathematics (AREA)
  • Composite Materials (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan composiciones y métodos para la generación o el tratamiento de perforaciones crónicas en la membrana timpánica mediante la modulación de la actividad del HB-EGF; en los métodos de la invención, una membrana timpánica perforada crónicamente se pone en contacto tópicamente con una dosis eficaz de factor de crecimiento epidérmico de unión a la heparina, HB-EGF, o un agente que tiene actividad de HB-EGF, durante un período suficiente para proporcionar una curación mejorada de la perforación de la membrana; en algunas modalidades la dosis de HB-EGF se proporciona en una formulación de liberación sostenida; en otras modalidades se proporciona la administración regular de una formulación de liberación no sostenida; en algunas modalidades, una formulación de liberación sostenida es biodegradable; en otras modalidades la liberación sostenida está provista por un dispositivo, por ejemplo una bomba u otro dispositivo de liberación.
MX2020001319A 2013-05-15 2015-11-13 Modulacion de la actividad del factor de crecimiento epidermico de union a la heparina para curar la membrana timpanica. MX2020001319A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361823749P 2013-05-15 2013-05-15

Publications (1)

Publication Number Publication Date
MX2020001319A true MX2020001319A (es) 2020-03-20

Family

ID=51898980

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015015774A MX2015015774A (es) 2013-05-15 2014-04-09 Modulación de la actividad del factor de crecimiento epidérmico de unión a la heparina para curar la membrana timpánica.
MX2020001319A MX2020001319A (es) 2013-05-15 2015-11-13 Modulacion de la actividad del factor de crecimiento epidermico de union a la heparina para curar la membrana timpanica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015015774A MX2015015774A (es) 2013-05-15 2014-04-09 Modulación de la actividad del factor de crecimiento epidérmico de unión a la heparina para curar la membrana timpánica.

Country Status (26)

Country Link
US (4) US20160074476A1 (es)
EP (2) EP3708181A1 (es)
JP (1) JP6316943B2 (es)
KR (1) KR102318748B1 (es)
CN (2) CN113559242A (es)
AU (2) AU2014265901B2 (es)
BR (2) BR122020011229B1 (es)
CA (1) CA2912411C (es)
CY (1) CY1123464T1 (es)
DK (1) DK2996709T3 (es)
ES (1) ES2805002T3 (es)
HR (1) HRP20200971T1 (es)
HU (1) HUE049294T2 (es)
IL (2) IL242454B (es)
LT (1) LT2996709T (es)
MX (2) MX2015015774A (es)
PH (2) PH12015502577B1 (es)
PL (1) PL2996709T3 (es)
PT (1) PT2996709T (es)
RS (1) RS60412B1 (es)
RU (2) RU2018146249A (es)
SG (1) SG11201509347UA (es)
SI (1) SI2996709T1 (es)
UA (1) UA120037C2 (es)
WO (1) WO2014186075A2 (es)
ZA (1) ZA201508289B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102634748B1 (ko) 2018-06-15 2024-02-13 삼성전자주식회사 포토 마스크용 펠리클 및 이의 제조 방법
AU2020319755A1 (en) * 2019-07-31 2022-03-10 Astellas Pharma Inc. Pharmaceutical composition for otic administration
KR102084146B1 (ko) * 2019-09-03 2020-03-04 (주)제이앤킴 이관 기능부전 치료를 위한 이관 내 삽입 스텐트
EP4103197A4 (en) * 2020-02-13 2024-02-14 Spiral Therapeutics Inc. TREATMENT OF OTIC DISEASES AND CONDITIONS
JPWO2022065404A1 (es) * 2020-09-25 2022-03-31
US11984398B2 (en) 2021-03-08 2024-05-14 Changxin Memory Technologies, Inc. Semiconductor structure and manufacturing method thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
JPH07503943A (ja) 1991-10-29 1995-04-27 クローバー　コンソリデイテッド，リミテッド 封入及び薬剤放出に有用な架橋性の多糖類、ポリカチオン及び脂質
US6514533B1 (en) * 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
WO1997041899A1 (en) 1996-05-03 1997-11-13 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
AU9785598A (en) 1997-10-03 1999-04-27 Texas Pharmaceuticals, Inc. Improved dual chamber syringe apparatus
US6191109B1 (en) * 1997-10-31 2001-02-20 Children's Hospital, Inc. Methods of treating intestinal ischemia using heparin-binding epidermal growth factor
AU760664B2 (en) * 1998-04-17 2003-05-22 Angiogenix, Inc. Therapeutic angiogenic factors and methods for their use
CA2395902A1 (en) 1999-12-28 2001-07-05 Asger Lau Dalmose Dual chamber syringe with a dual function piston
WO2001070269A1 (en) 2000-03-24 2001-09-27 Akzo Nobel N.V. Keratinocyte growth inhibitors and hydroxamic acid derivatives
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US20090148486A1 (en) * 2005-04-28 2009-06-11 Helen Lu Compositions and methods for treating pulp inflammations caused by infection or trauma
BRPI0612121A2 (pt) * 2005-06-30 2016-09-06 Anthrogenesis Corp método de reparo de uma membrana timpânica que tenha uma deformidade, e, biotecido de colágeno
EP1949907B1 (en) 2005-09-28 2014-07-02 Kagoshima University Novel application of heparin-binding epidermal growth factor-like growth factor for medical purposes
US8093213B2 (en) 2007-04-30 2012-01-10 Nationwide Children's Hospital, Inc. Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation
US20090192079A1 (en) * 2007-10-09 2009-07-30 Genzyme Corporation Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen
EP2249863A4 (en) * 2008-01-22 2011-12-28 Omnio Healer Ab METHOD OF ENHANCING WOUND HEALING
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
JP5398712B2 (ja) * 2008-06-26 2014-01-29 眞一 金丸 鼓膜または外耳道再生剤
EP2468771A4 (en) * 2009-08-17 2013-06-05 Forerunner Pharma Res Co Ltd PHARMACEUTICAL COMPOSITION WITH AN ANTIBODY TO HB-EGF AS AN ACTIVE SUBSTANCE
CN103037892A (zh) * 2010-02-22 2013-04-10 布里格姆妇女医院 诱导血管生成的组合物和方法
US8556854B2 (en) 2010-07-22 2013-10-15 Becton, Dickinson And Company Dual chamber syringe with retractable needle
CN103764071B (zh) * 2011-07-11 2017-02-15 澳大利亚耳科学研究所 鼓室修补器械
US9821118B2 (en) 2011-09-02 2017-11-21 Unl Holdings Llc Automatic reconstitution for dual chamber syringe
MX2014015668A (es) * 2012-06-28 2015-07-14 Univ Tulane Composiciones polimerizables selectivamente y metodos de uso in vivo.
US9814779B2 (en) * 2013-04-09 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Crosslinked chitosan-lactide hydrogels

Also Published As

Publication number Publication date
SG11201509347UA (en) 2015-12-30
CA2912411C (en) 2022-10-25
MX2015015774A (es) 2016-07-26
AU2014265901A1 (en) 2015-11-26
HUE049294T2 (hu) 2020-09-28
US20220111006A1 (en) 2022-04-14
HK1217166A1 (en) 2016-12-30
RU2015148636A (ru) 2017-06-20
BR112015028367A2 (pt) 2017-07-25
PH12015502577B1 (en) 2021-03-10
IL273329A (en) 2020-04-30
UA120037C2 (uk) 2019-09-25
IL242454B (en) 2020-05-31
CY1123464T1 (el) 2022-03-24
PT2996709T (pt) 2020-07-14
PH12015502577A1 (en) 2016-02-29
ES2805002T3 (es) 2021-02-10
US20160074476A1 (en) 2016-03-17
US20240342243A1 (en) 2024-10-17
HRP20200971T1 (hr) 2020-10-02
AU2019200630B2 (en) 2020-08-27
CN113559242A (zh) 2021-10-29
KR102318748B1 (ko) 2021-10-27
PH12020551126A1 (en) 2021-12-13
ZA201508289B (en) 2019-02-27
PL2996709T3 (pl) 2021-02-08
WO2014186075A3 (en) 2015-06-04
WO2014186075A2 (en) 2014-11-20
CN105555296A (zh) 2016-05-04
CA2912411A1 (en) 2014-11-20
RU2018146249A (ru) 2019-01-18
DK2996709T3 (da) 2020-06-02
EP2996709A2 (en) 2016-03-23
US11963998B2 (en) 2024-04-23
AU2014265901B2 (en) 2018-11-08
SI2996709T1 (sl) 2020-09-30
EP3708181A1 (en) 2020-09-16
BR122020011229B1 (pt) 2022-06-07
US20180256684A1 (en) 2018-09-13
JP2016520080A (ja) 2016-07-11
AU2019200630A1 (en) 2019-02-21
US11235027B2 (en) 2022-02-01
LT2996709T (lt) 2020-08-10
IL273329B (en) 2021-05-31
EP2996709B1 (en) 2020-05-06
JP6316943B2 (ja) 2018-04-25
RS60412B1 (sr) 2020-07-31
EP2996709A4 (en) 2016-11-16
BR112015028367B1 (pt) 2020-12-01
KR20160013063A (ko) 2016-02-03
RU2676483C2 (ru) 2018-12-29

Similar Documents

Publication Publication Date Title
PH12015502577A1 (en) Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
MX2020012591A (es) Soluciones midriaticas y antiinflamatorias inyectables, estables y libres de conservantes.
PH12015500115B1 (en) Glucagon analogues
MX373307B (es) Compuestos de biaril-amida como inhibidores de cinasa.
EP4628042A3 (en) ROBOTIC SURGICAL DEVICES AND SYSTEMS
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
MX378814B (es) Armazón de colágeno y glicosaminoglicano coinjertado con una población de células madre abcb5+ y usos del mismo.
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
MX377267B (es) Tratamiento de cáncer con dihidropirazino-pirazinas.
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
CO6551731A2 (es) Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica
MX2017016096A (es) Agente antihipertensivo.
PH12015502282A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
MX386144B (es) Inmunopotenciador.
MX2016005006A (es) Composicion para prevenir a tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito.
MX386151B (es) Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.
EA201690445A1 (ru) Лечение рака
CY1122538T1 (el) Συμπλεγματα χονδροϊτινης για διαδερμικη απορροφηση
CY1118633T1 (el) Χρηση pidotimod για την θεραπευτικη αγωγη ατοπικης δερματιτιδας
EA201690551A1 (ru) Применение гидроксипропил хитозана для лечения онихомикоза